Bolt Biotherapeutics (FRA:6LP) Debt-to-Equity : 0.18 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics Debt-to-Equity?

Bolt Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €2.55 Mil. Bolt Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €15.99 Mil. Bolt Biotherapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €103.38 Mil. Bolt Biotherapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.18.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bolt Biotherapeutics's Debt-to-Equity or its related term are showing as below:

FRA:6LP' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.22 Med: 0.05 Max: 0.18
Current: 0.18

During the past 6 years, the highest Debt-to-Equity Ratio of Bolt Biotherapeutics was 0.18. The lowest was -0.22. And the median was 0.05.

FRA:6LP's Debt-to-Equity is ranked worse than
52.97% of 1076 companies
in the Biotechnology industry
Industry Median: 0.15 vs FRA:6LP: 0.18

Bolt Biotherapeutics Debt-to-Equity Historical Data

The historical data trend for Bolt Biotherapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics Debt-to-Equity Chart

Bolt Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.22

-0.10

0.10

0.13

0.18

Bolt Biotherapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial														0.13	0.14	0.15	0.16	0.18

Competitive Comparison of Bolt Biotherapeutics's Debt-to-Equity

For the Biotechnology subindustry, Bolt Biotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bolt Biotherapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's Debt-to-Equity falls into.

Bolt Biotherapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bolt Biotherapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.551	+	15.99)	/	103.383
	=	0.18

Bolt Biotherapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.551	+	15.99)	/	103.383
	=	0.18

Bolt Biotherapeutics (FRA:6LP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bolt Biotherapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bolt Biotherapeutics (FRA:6LP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (FRA:6LP) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BOLT:USA 6LP:Germany

Address

900 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.boltbio.com

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.

Bolt Biotherapeutics (FRA:6LP) Headlines

No Headlines